Rhinomed is pleased to announce it has been advised by Medical Device Safety Service GmbH (MDSS) that an Authorized Representative’s Mandate according to the EU Regulation 2017/745 (MDR) is in place. As a result, Rhinomed has been issued a CE Certificate No.: 431330 for the new Rhinoswab. The successful registration and conformity with the relevant … Read more
Rhinomed is pleased to announce the appointment of Associate Professor John McBain AO as a Non Executive Director of the Company, effective immediately. Assoc. Prof. McBain is the former Head of Reproductive Services at The Royal Women’s Hospital in Melbourne, Australia. He is also the former President of the Fertility Society of Australia, and was … Read more
Rhinomed is pleased to report an important update on its Rhinoswab™ clinical program. In December 2020 the company established that the Rhinoswab was comparable to existing standard of care nasal swabs in detecting the SARS-CoV-2 virus in RT-PCR testing. This study was undertaken at the VIDRL (Peter Doherty Institute). Since December the company has further … Read more
Rhinomed is pleased to announce that the Australian Taxation Office has of today’s date refunded the R&D tax incentive amount in respect of the FY20 income tax year. The Company had previously lodged an application with AusIndustry which was approved. The Company then submitted its FY20 tax return, detailing the R&D tax incentive refund amount. … Read more
Rhinomed is pleased to provide its report for the half year ended 31 December 2020. Commenting on the results, Rhinomed’s CEO Michael Johnson said “2020 produced unheralded uncertainty in all of our major markets, despite this Rhinomed continued its strong focus on delivering value to our customers, clinicians and retail partners right across the world. … Read more
Rhinomed is pleased to report positive data from its lab-based spiking study of Rhinomed’s new Rhinoswab conducted at the Victorian Infectious Diseases Reference Laboratory (VIDRL), part of The Peter Doherty Institute for Infection and Immunity (The Doherty) in Melbourne. The study’s objective was to demonstrate efficacy in detecting the SARS-CoV-2 virus at both low and … Read more
Rhinomed has successfully registered its easy to use, high load capturing, comfortable nasal swab with the Australian Therapeutic Goods Administration (TGA) as a Class 1 device. The new swab can comfortably collect samples from both nostrils simultaneously to test for the presence of upper respiratory tract diseases including influenza and coronavirus including SARS-CoV-2. The unique … Read more
Rhinomed Limited is pleased to announce that it has successfully registered its novel nasal swab with the US FDA as a Class 1 device to collect samples from the nose to detect upper respiratory tract diseases including influenza and coronavirus strains. The successful registration and conformity with the relevant standards means that Rhinomed’s novel nasal … Read more
Rhinomed Limited (ASX:RNO OTCQB:RHNMF), a leader in nasal airway and respiratory technology, is advanced in developing a new high-yielding nasal swab that can collect samples from the nose to test for the presence of upper respiratory tract diseases, including influenza and coronavirus strains. Read a full copy of the report here.
Rhinomed Limited (ASX:RNO, OTCQB: RHNMF), a leader in nasal and respiratory technology and the maker of Mute™ and Pronto™, can report its FY 20 Q4 results and preliminary unaudited full year results. After a record FY20 Q3 result the company was on track to reach its full year planned targets. Confirmation during the quarter that … Read more
Rhinomed Limited (ASX:RNO, OTCQB: RHNMF), a leader in nasal and respiratory technology and the maker of Mute™ and Pronto™, today announces it has received purchase orders confirming a major distribution expansion of its Pronto Clear nasal decongestion technology within one of the largest and leading pharmacy and drugstore chains in the USA. Read a full … Read more
Rhinomed (ASX:RNO) is pleased to advise investors it has signed a 12-year exclusive licensing agreement of its nasal platform technology with Columbia Care LLC, the largest and most experienced provider of cannabis-based products and services in the United States (U.S.). Read a full copy of the report here.